Google� (NASDAQ: GOOG ) Translate has added supports for five more languages spoken by more than 183 million people worldwide, the company announced this week. Google Translate now handles more than 70 languages.
The five new languages, with Google facts on each, are:
Bosnian: �The official language in Bosnia and Herzegovina. Cebuano: �One of the languages from the Phillipines. Hmong: �Spoken by the Hmong people across China, Vietnam, Laos, and Thailand. Javanese: �The second-most-spoken language in Indonesia, with 83 million native speakers. Marathi: �An Indian language with 73 million native speakers. Google Translate already supports several other Indian languages: Bengali, Gujarati, Hindi, Kannada, Tamil, Telugu and Urdu.Except Bosnian, Google says the new languages are in "alpha" testing, meaning the Google translation quality may not be perfect, but will improve over time. Google Translate can be accessed on the Google Translate homepage, via Chrome, in Gmail, or on an Androi or iOS device.�
Top 10 International Stocks To Buy For 2015: Physicians Realty Trust (DOC)
Physicians Realty Trust, incorporated on April 9, 2013, is a real estate investment trust (REIT). The Company is a self-managed healthcare real estate company. The Company is engaged in acquiring, developing, owning and managing healthcare properties that are leased to physicians, hospitals and healthcare delivery systems. The Company invests in real estate that is integral to providing healthcare services. The Company�� properties are located on a campus with a hospital or other healthcare facilities or strategically located and affiliated with a hospital or other healthcare facilities. The Company�� principal investments will include medical office buildings, outpatient treatment facilities, acute and post-acute care hospitals, as well as other real estate integral to healthcare providers. The Company�� initial portfolio will consist of 19 medical office buildings located in 10 states with approximately 528,048 net leasable square feet. Effective August 27, 2013, Physicians Realty Trust acquired an undisclosed hospital, located in Plano, Texas, an owner and operator of hospital. In September 2013, Physicians Realty Trust completion of the sale-leaseback of the surgical hospital and adjacent medical office building occupied by the Foundation Surgical Hospital of El Paso, L.L.C. In October 2013, Physicians Realty Trust announced the completion of the acquisition of the Foundation Outpatient Care Building located in Oklahoma City, OK. Effective January 8, 2014, Physicians Realty Trust acquired an undisclosed ambulatory surgery center, located in Great Falls, Montana. In February 2014, the Company's operating partnership, Physicians Realty L.P., closed on the purchase and leaseback of four medical office buildings to an Atlanta, Georgia-based family medical practice.
The Company�� Surgical Hospital-New Orleans, Louisiana property is a 57,000 square foot, 42-bed acute care surgical hospital with six operating rooms. The hospital specializes in ortho/neuro spine surgery, orthopedics, ! weight loss surgery and other scheduled general surgery procedures. Surgical Hospital and Medical Office Building-El Paso, Texas property is a 77,000 square foot, 40-bed acute care hospital with six operating rooms. The Company's initial portfolio was acquired or developed by healthcare real estate funds managed by B.C. Ziegler & Company (Ziegler), a specialty investment banking firm focused on the healthcare industry, and another subsidiary of The Ziegler Companies, Inc. As part of its formation transactions, the Ziegler Funds will contribute their ownership interests in these properties to its operating partnership.
Advisors' Opinion:- [By Marc Bastow]
Healthcare REIT Physicians Realty Trust (DOC) was right up their with Ford in raising its quarterly dividend 25%, to 22.5 cents per share, payable Feb. 7 to shareholders of record as of Jan. 24.
DOC Stock Dividend Yield: 7.02%
Top Quality Stocks To Watch Right Now: ViroPharma Incorporated(VPHM)
ViroPharma Incorporated, a biotechnology company, develops and commercializes therapeutic products that address serious diseases in the United States and internationally. It focuses on developing products used by physician specialists or in hospital settings. The company markets and sells Cinryze, a C1 esterase inhibitor therapy for the routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema, a life-threatening genetic disorder; and Vancocin HCl capsule, an oral capsule formulation for the treatment of C. difficile-associated diarrhea (CDAD) and to treat enterocolitis caused by staphylococcus aureus, including methicillin-resistant strains. It also offers Plenadren, an orphan drug for treatment of adrenal insufficiency in adults; Buccolam, a oromucosal solution for treatment of prolonged, acute, and convulsive seizures in infants, toddlers, children, and adolescents; and maribavir, an antiviral compound for the treatment o f CMV disease through a license agreement with GlaxoSmithKline. The company?s primary development programs include Cinryze, a C1 esterase inhibitor for management of hereditary angioedema; and VP 20621, a non-toxigenic strain of C. difficile. Its clinical stage drug candidate comprises VP-20629 for the treatment of Friedreich?s Ataxia. The company sells its products directly to wholesale drug distributors and specialty pharmacies/distributors. ViroPharma Incorporated was founded in 1994 and is headquartered in Exton, Pennsylvania.
Advisors' Opinion:- [By John Udovich]
Small cap orphan drug stocks Zalicus Inc (NASDAQ: ZLCS), Omeros Corporation (NASDAQ: OMER) and Viropharma Inc (NASDAQ: VPHM) have been active lately thanks to good news about their orphan drug treatments. In case you aren�� familiar with the term, orphan drug designation by the FDA is granted for drugs targeting conditions affecting 200,000 or fewer US patients annually that are expected to provide significant therapeutic advantage over existing treatments. The designation will also qualify companies for benefits across all stages of drug development, such as�accelerated approval processes, seven years of market exclusivity�after marketing approval, tax credits on�any US�clinical trials, grants and waiver of certain administrative fees.
Top Quality Stocks To Watch Right Now: Universal Biosensors Inc (UBI)
Universal Biosensors, Inc. (Universal Biosensors) is an early-stage specialist medical diagnostics company focused on the research, development and manufacture of in vitro diagnostic test devices for consumer and professional point-of-care use. The Company uses its electrochemical cell technology platform to develop tests for a number of different markets. The Company�� principal activities are research and development, commercial manufacture of approved medical or testing devices and the provision of services including contract research work. The Company operates primarily in Australia. The Company uses its electrochemical cell technology platform to develop tests for a number of different markets. The Company has rights to a portfolio comprising patent applications owned by its wholly owned subsidiary, Universal Biosensors Pty Ltd, and a number of patents and patent applications licensed to the Company by LifeScan, Inc., an affiliate of Johnson & Johnson Company. Advisors' Opinion:- [By Namitha Jagadeesh]
Banco Popolare SC (BP) declined 3.5 percent to 1.29 euros and Unione di Banche Italiane SCPA (UBI) slid 2.3 percent to 4.93 euros after Societe Generale SA reduced its 12-month price forecast on the shares.
Top Quality Stocks To Watch Right Now: Biogen Idec Inc(BIIB)
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include the AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin?s lymphoma (NHL); TYSABRI to treat relapsing MS; FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. Biogen Idec Inc.?s products under Phase III consist of PEGylated interferon beta-1a designed to prolong the effects and reduce the dosing frequency of interferon beta-1a; BG-12 for the treatment of MS; Daclizumab, a monoclonal antibody in relapsing MS; Long-lasting factor IX and VIII fusion protein for the treatment of hemophilia B; GA101, a monoclonal antibody for t he treatment of chronic lymphocytic leukemia and NHL; and Dexpramipexole, an orally administered small molecule for the treatment of amyotrophic lateral sclerosis. The company?s Phase I clinical trial products include Anti-LINGO for use in multiple sclerosis, Neublastin for use in neuropathic pain, CD40L for use in systemic lupus erythematosus, ANTI-TWAEK humanized monoclonal antibody for TWEAK, and BIIB037 for use in Alzheimer's disease; and Phase II clinical trial product comprises OCRELIZUMAB, a humanized monoclonal antibody for treating CD20. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; Swedish Orphan Biovitrum AB; Abbott Biotherapeutics Corp; and Vernalis plc. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.
Advisors' Opinion:- [By Ben Levisohn]
The SPDR S&P Biotech ETF (XBI) has fallen 1.3% to $128.69 at 2:10 p.m., as Biogen Idec (BIIB) has dropped 4.2% to $293.91 and Regeneron Pharmaceuticals (REGN) has declined 3.7% to $291.81. Even Gilead Sciences (GILD), which managed to buck yesterday’s weakness, has dipped 0.4% to $73.59.
- [By Ben Levisohn]
Shares of Gilead Sciences have ticked up 0.1% to $73.69 at 1:58 p.m. today, a solid day given Amen’s (AMGN) 0.7% drop to $125.53 and Biogen Idec’s (BIIB) 0.7% decline to $307.76.The iShares Nasdaq Biotechnology ETF (IBB) has fallen 0.5% to $240.34, while the SPDR S&P Biotech ETF (XBI) has dropped 1.2% to $1434.68.
- [By Ben Levisohn]
Might that be the reason that Gilead’s shares are climbing today, even as most other big biotech names get clobbered. Gilead has risen 3.2% to $75.17 at 12:15 p.m. today, while Amgen (AMGN) has fallen 5.2% after missing earnings forecasts and Biogen Idec (BIIB) has dropped after it too disappointed. The SPDR S&P Biotech ETF (XBI) has declined 2.2% to $131.13, while the iShares Nasdaq Biotechnology ETF (IBB) is off 1.4% at $231.54.
- [By Peter Stephens]
In addition, sector peer Biogen (NASDAQ: BIIB ) has received European Commission aproval for its new multiple sclerosis drug, Tecfidera, and will launch the product in H1 2014. The potential in Europe for the drug seems vast, since it has become the most prescribed pill for the treatment of multiple sclerosis in the U.S. since Biogen gained approval for it in 2013.
Top Quality Stocks To Watch Right Now: Blackrock Enhanced Equity Dividend Trust (BDJ)
BlackRock Enhanced Dividend Achievers Trust (the Trust) is a diversified closed-end management investment company. The Trust�� primary investment objective is to seek current income and current gains, with a secondary objective of long-term capital appreciation. The Trust seeks to achieve these objectives by investing in common stocks that pay above average dividends and have the potential for capital appreciation and by utilizing an option writing strategy to enhance distributions paid to the Trust�� shareholders.
Under normal market conditions, the Trust will invest at least 80% of its total assets in common stocks that are included in the universe of common stocks of issuers, which Mergent has determined are Dividend Achievers and options with exposure to such stocks. From time to time, the Trust may invest up to 20% of its total assets in investments without exposure to the Dividend Achievers universe. As part of its investment strategy, the Trust intends to employ a strategy of writing (selling) covered call and put options on individual common stocks, indices of securities, sectors of securities and baskets of securities.
Advisors' Opinion:- [By Robert Hsu]
Name Type of Security� Recommendation� Kinder Morgan Energy Partners L.P. (NYSE: KMP) � MLP August 15, 2013� TeeKay LNG Partners L.P.� (NYSE: TGP) � MLP September 16, 2013� PowerShares S&P 500 BuyWrite Portfol ETF� (NYSE Arca: PBP)� Buy-Write ETF September 30, 2013� Madison Covered Call Equity Strtgy Fd (NYSE: MCN)� Buy-Write ETF September 30, 2013� Nuveen Equity Premium Opportunity Fund (NYSE: JSN)� Buy-Write ETF September 30, 2013� BlackRockEnhanced Dividend Achievers Tr (NYSE: BDJ)� Buy-Write ETF September 30, 2013� Vornado Realty Trust � (NYSE: VNO)� Real Estate
Investment
Trust September 26, 2013�Robert Hsu is the editor of Permanent Wealth Investor and a former hedge fund portfolio manager at Wall Street powerhouse Goldman Sachs. He retired from Goldman at age 31. He since has come out of retirement to establish and preside over his money management firm, Absolute Return Capital Advisors. His retirement experience has given him his current mission: helping investors like you achieve their goal of comfortable retirement through profitable income strategies.
- [By Robert Hsu]
Here are four to consider:
PowerShares S&P 500 BuyWrite ETF (PBP), yielding 4.09%
Madison/Claymore Covered Call & Equity Strategy (MCN), yielding 8.94%
Nuveen Equity Premium Opportunity Fund (JSN), yielding 9.19%
BlackRock Enhanced Dividend Achievers (BDJ), yielding 7.39%
The yield on these funds is very attractive. Even more attractive is the fact that many buy-write funds actually are selling at a discount to their net asset value.
No comments:
Post a Comment